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Background: Antihistamines constitute the first line of therapy for allergic conjunctivitis, and 
are safe and effective in relieving the signs and symptoms of ocular allergy. Despite this, they 
are less effective than some other drugs in relieving delayed symptoms of allergic conjunctivitis. 
Recent evidence suggests that changes in the conjunctival epithelium may underlie aspects of 
delayed reactions. In this study we compared two antihistamines, olopatadine and alcaftadine, 
for their ability to modify epithelial cell changes associated with allergic conjunctivitis at time 
points selected to reflect late-phase reactions.
Methods: Studies employed a modified conjunctival allergen challenge model. Sensitized 
mice were challenged with topical allergen with or without drug treatments. Treatment groups 
were assayed for acute-phase (15 minutes) and delayed-phase (24 hours) responses. Groups 
were scored for allergy symptoms (redness, itch, tearing, and edema) and for conjunctival mast 
cell numbers. Delayed-phase groups were also examined for eosinophil numbers and for tight 
junctional protein expression.
Results: Olopatadine-treated and alcaftadine-treated animals had similar efficacy profiles and 
mast cell numbers, suggesting both were effective at ameliorating symptoms of the acute phase. 
In contrast, alcaftadine-treated animals had significantly lower conjunctival eosinophil infiltra-
tion than either controls or olopatadine-treated animals. Allergen challenge caused a significant 
decrease in expression of the junctional protein, ZO-1, and this decrease was prevented by 
alcaftadine but not by olopatadine.
Conclusion: Alcaftadine displays therapeutic properties beyond its antihistamine action. These 
include an ability to reduce conjunctival eosinophil recruitment, and a protective effect on 
epithelial tight junction protein expression.
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Introduction
Allergic conjunctivitis affects over 20% of the general population, and includes 
  seasonal allergic conjunctivitis and perennial allergic conjunctivitis.1,2 The varying 
manifestations of allergic conjunctivitis reflect a Type 1, Type 4, or combined IgE-
dependent hypersensitivity inflammatory response to an allergen leading to activation 
of mast cells, basophils, eosinophils, and other mediators.3 Allergen load, degree of 
dilution within the tear film, expression of adhesion molecules by epithelial cells 
within the ocular surface, and several other environmental and physiological factors 
all dictate the initiation and magnitude of the allergic response. By affecting passage Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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towards the basement membrane, where allergen proteins 
cross-link with IgE and incite the allergic cascade, these 
processes also represent potential upstream targets of antial-
lergy treatment.
One of the protective elements of the ocular surface that 
must be overcome in order for an allergen to elicit a positive 
response are the tight junctions of the conjunctival epithe-
lium. Tight junctions are cell membrane protein complexes 
that link the cytoskeletons of adjacent epithelial cells for 
adhesion and stability. They comprise occludin and claudin 
transmembrane proteins that form a selectively permeable 
seal and regulate paracellular   transport.4 Within healthy 
conjunctiva, tight junctions act as a nearly impermeable bar-
rier and allow the passage of only nutrients and water, while 
blocking the passage of toxins, microorganisms, and aller-
gens. In diseased conjunctiva, the function and organization 
of the tight junction is diminished, and the expression of 
junctional proteins is disrupted, thereby compromising the 
gatekeeping function of the epithelial layer.5
Recent work has provided evidence of a role for tight junc-
tions in the pathology of allergy. Several common allergens 
have been implicated in changes in key tight junction proteins. 
For example, house dust mite fecal pellets have been shown 
to contain proteolytic enzymes that break down occludins, 
such as zonula occludens 1 (ZO-1).6 This proteolysis leads to 
tight junction cleavage and increased epithelial permeability.6 
Similarly, pollen peptidases from several   species have been 
shown to degrade epithelial tight junctions, either directly or 
indirectly, based upon the loss of occludin, claudin-1, and ZO-1 
immunofluorescent staining.7 In comparisons of patients with 
seasonal allergic conjunctivitis and normal controls, the 
patients with seasonal allergic conjunctivitis exhibit a down-
regulation of epithelial cell adhesion proteins and cytoskeletal 
elements.5 Collectively, these data suggest that changes in tight 
junction protein expression, assembly, or both, may participate 
in the etiology of conjunctival allergy.
Steroids are typically a secondary choice for treatment 
of allergic conjunctivitis.8 They are effective in treating 
chronic allergy, but have significant side effects, including a 
risk of increased intraocular pressure. Several in vitro studies 
have shown that glucocorticoids exert a stabilizing effect on 
tight junctions and on epithelial permeability.9,10 While a 
specific connection between steroid effects on epithelial tight 
junctions and their efficacy in late-phase conjunctivitis 
remains to be established, these results are intriguing in light 
of the data connecting allergic conjunctivitis and changes in 
tight junctional proteins.
Alcaftadine is a tricyclic piperidine aldehyde that exhibited 
antihistamine activity in several well established in vivo mod-
els.11 It also showed anti-inflammatory activity in the allevia-
tion of eosinophil infiltration in a guinea pig model of allergic 
conjunctivitis.12 In addition, alcaftadine has a unique spectrum 
of histamine receptor specificity: it has high affinity for both 
H1 and H2 histamine receptors (3.1 and 58 nM Ki, respectively), 
and also exhibits H4 receptor antagonism in vitro.12 Collec-
tively, these observations suggest that alcaftadine may have 
properties that distinguish it from other antihistamines.
The purpose of this study was to compare the effects of 
alcaftadine 0.25% and an active control (olopatadine 0.1% 
ophthalamic solution; Alcon Laboratories, Fort Worth TX) 
on the expression of key tight junction proteins within a 
murine model of allergic conjunctivitis. Like alcaftadine, 
olopatadine has been shown to have anti-inflammatory prop-
erties in vitro.13,14 The expression of two junctional proteins, 
ZO-1 and E-cadherin, were determined in both treated and 
untreated allergen-challenged mouse eyes using confocal 
microscopy. In addition, the extent of eosinophil recruitment 
was measured in all   experimental groups.
Materials and methods
Animals
Eighty BALB/c mice supplied by Jackson Laboratories 
(Bar Harbor, ME) were used in this study. The mice were 
housed in the facilities of the Woodruff Health Sciences 
Center of Emory University (Atlanta, GA) and maintained 
in accordance with the Association for Research in Vision 
and Ophthalmology Resolution on the Use of Animals in 
Research and internal animal use guidelines.
Sixteen mice were enrolled per treatment arm. Eight mice 
per treatment arm were evaluated for early-phase assessment 
(clinical signs and symptom and mast cell   density) and eight 
mice per arm were evaluated for delayed-phase assessments 
(eosinophil recruitment, tight junction protein expression) as 
shown in Table 1. All animals received a thorough examination 
to ensure that there was no sign of pre-existing ocular inflam-
mation. The five treatment arms were: naïve (no sensitization, 
no allergen   challenge [NS/NC]); sensitized, challenged (no 
treatment [S/C]); sensitized, challenged, vehicle-treated 
(vehicle); sensitized, challenged, olopatadine-treated 
(olopatadine); and sensitized, challenged, alcaftadine-treated 
(alcaftadine). The naïve group provided a baseline to assess 
the effects of challenge, while the vehicle group ensured that 
any effects observed in out two treatment groups were due to 
the active agents. Following experimental   treatments (at times Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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indicated), animals were euthanatized by cervical dislocation 
and tissues were removed for assay.
Test articles/randomization
Alcaftadine 0.25% w/v ophthalmic solution was the experi-
mental treatment, olopatadine 0.1% w/v ophthalmic solu-
tion was used as an active control, and alcaftadine 
ophthalmic solution vehicle was used as a placebo control. 
This vehicle comprised isotonic saline buffered with sodium 
phosphate and ethylenediamine tetraacetic acid to pH 7.4. 
The vehicle also contained 0.005% w/v benzalkonium 
chloride as a preservative. Vistakon Pharmaceuticals, LLC 
(Jacksonville, FL) provided the alcaftadine ophthalmic stock 
solution and vehicle stock solution. A technician not involved 
in the study performed all masking and ran  domization proce-
dures. Prior to sensitization, mice were randomized to one of 
five treatment arms shown in Table 1.
Sensitization (days 1–14)
Conjunctival allergen challenge involves direct ocular instil-
lation of antigen in animals sensitized to elicit an allergic 
response. Mice were injected intraperitoneally with 1 mg of 
aluminum hydroxide conjugated with short ragweed pollen 
extract (2000 AU/mouse; ALK Laboratories Round Rock, 
TX) on days 1 and 14. Concomitantly, aluminum hydroxide-
conjugated short ragweed pollen extract 1000 AU/µL was 
topically administered into the eye on days 1, 2, 3, 7, and 14 
(25 µg/eye). Thereafter, mice were topically challenged in 
both eyes once per week with short ragweed pollen extract 
1000 AU/µL without aluminum hydroxide.
Challenge (days 28–30)
Four weeks after the initial sensitization, mice were chal-
lenged bilaterally by instilling affinity-purified short ragweed 
pollen 0.5 mg/mL topically (10 µL/eye) for three consecutive 
days. Control mice were sensitized in a similar manner and 
challenged using antigen solution. The specificity of the 
allergic responses was confirmed by challenging sensitized 
mice with experimentally irrelevant antigens. After the 
final challenge, clinical responses were recorded within 
the first 30 minutes and graded for symptoms of allergic 
conjunctivitis.
Dosing (days 28–30)
Dosing was performed prior to challenge on the three con-
secutive challenge days that comprised the final three days 
of the study. One eye received study drug and the other eye 
received placebo. Ten microliters of the assigned test article 
were administered topically twice, ie, at two hours and at 
one hour prior to the final topical challenges. The test article 
was administered according to the randomization scheme 
shown in the table1. For the delayed-phase group, two addi-
tional doses were given at hours 1 and 2 after challenge prior 
to sacrifice 24 hours after challenge.
Early-phase assessments
Following the final allergen challenge, ocular symptoms were 
evaluated in a double-blinded fashion and graded on a 
0–4 scale by an ophthalmologist unaware of the group to 
which each mouse was randomized. Mice were placed in a 
laminar flow hood under ambient light conditions for 
evaluation.
The behavioral responses of the mice were continuously 
recorded between 10 and 15 minutes after challenge, and 
their squinting/face-washing score was graded based on 
numbers of continuous actions. The mice were videotaped 
to allow cross-checking of these numerical scores.
After the final challenge, conjunctival edema, lid edema, 
redness, and tearing were evaluated 15 minutes after   challenge. 
The cumulative clinical score was calculated as the sum of 
the scores of each of these four parameters (0–16). A more 
detailed assessment of the criteria used has been described 
elsewhere.15
Mice in the early-phase group were sacrificed 30 m  inutes 
after conjunctival allergen challenge and tissues were 
processed for mast cell density analysis. Collected tissues 
were fixed in 4% paraformaldehyde and embedded in 
  historesin (Leica Instruments GmbH, Nussloch, Germany). 
Serial   sagittal sections (3 µm) were stained with toluidine 
blue for mast cell identification. Three consecutive tissue sec-
tions from each eye were examined, and mast cells were 
Table 1 Treatment Group Properties
Group Sensitization Allergen 
challenge
Treatment Early  
phase 
n
Late  
phase 
n
1 - - No treatment  
(NS/NC)
8 8
2 + + No treatment 
(S/C)
8 8
3 + + Alcaftadine  
vehicle
8 8
4 + + Olopatadine 0.1% 8 8
5 + + alcaftadine 0.25% 8 8
Abbreviations:  NS/NC,  no  sensitization,  no  challenge  (naïve  animals);  S/C, 
sensitized, challenged.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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counted under a 200× field microscope in a double-blinded 
fashion.
Delayed-phase assessments
Mice in the delayed-phase group were sacrificed at 24 hours 
after conjunctival allergen challenge. Collected tissues were 
fixed, embedded, and cut as described above. Tissue sections 
were stained with Giemsa and hematoxylin and eosin. 
  Eosinophil cell counts were determined in a double-blinded 
fashion as described for mast cell counting. For confocal 
microscopy, serial frozen sections (10 µm in thickness) were 
acetone fixed at -20°C for 10 minutes, then equilibrated in 
phosphate-buffered saline. Eosinophil infiltration was imaged 
by staining with an antibody to the eosinophil-specific major 
basic protein (antibody provided by HC Lee, Mayo 
Clinic, Rochester, MN) followed by anti-rat IgG fluorescein 
isothiocyanate conjugate (BD Pharmingen, San Diego, 
CA). Sections were counterstained for nucleic acid using 
Vectashield mounting medium with propidium iodide 
(Vector Labs, Burlingame, CA). Sections were cut and 
prepared similarly for ZO-1 and E-cadherin imaging. Sec-
tions were incubated with rabbit anti-ZO-1 and rat anti-E 
cadherin (both antibodies from Invitrogen, Carlsbad, CA). 
Primary antibodies were visualized with goat anti-rabbit 
IgG coupled with Alexa-568 (ZO-1) and goat anti-rat IgG 
coupled with Alexa-488. Both secondary antibodies were 
obtained from Invitrogen.
All of the images for ZO-1 and E-cadherin were captured 
using an Olympus FluoView fluorescence microscope 
(Olympus America Inc, Center Valley, PA). Fluorescence 
intensity values of ZO-1 and E-cadherin were measured using 
Image-Pro Plus software (version 6.2; Media Cybernetics 
Inc, Bethesda, MD, http://www.mediacy.com/). This pro-
gram uses an automated algorithm to identify regions of 
specific staining and calculates density of fluorescence signal. 
Eight such determinations were averaged, and the resulting 
data were analyzed using GraphPad PRISM version 5.00 
(GraphPad, San Diego, CA). Statistical significance was 
assessed by comparing all treatment groups using Tukey’s 
multiple comparison test. A P value of less than 0.05 was 
considered significant.
Results
Early-phase assessments
Sensitization and challenge induced significant increases in 
allergic signs and symptoms, including tearing and discharge, 
lid edema, conjunctival chemosis, and conjunctival redness 
(P , 0.001, Figure 1A). Although both olopatadine and 
alcaftadine were numerically superior to the S/C group, 
neither agent was statistically superior. Mast cell counts 
showed no significant differences between treatment groups 
(Figure 1B).
Late-phase assessments
Changes in conjunctival eosinophil number were exam-
ined by two methods. Tissue sections from each of the five 
t  reatment groups were stained for major basic protein, a 
specific eosinophil cell marker. Figure 2 shows the level 
of eosinophil staining is dramatically increased in both S/C 
(Figure 2B) and vehicle (Figure 2C) conjunctiva. This 
increase is reduced in animals receiving olopatadine 
(  Figure 2D) or alcaftadine (Figure 2E). Tissue sections 
were also stained for eosinophil cell counting; data from 
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Figure 1 Acute-phase assessments. Measures of acute response in the modified 
conjunctival  allergen  challenge  assay.  A)  Mean  values  of  summated  symptom 
scores for five treatment groups. Symptoms include tearing, lid edema, conjunctival 
chemosis, and conjunctival redness. All treatment groups are significantly different 
from untreated (NS/NC, P . 0.001). B) Mast cell counts from three consecutive 
conjunctival tissue sections observed under a 200× field microscope. No significant 
differences were observed between groups. Error bars indicate standard error in 
both (A and B).
Abbreviations:  NS/NC,  no  sensitization,  no  challenge  (naïve  animals);  S/C, 
sensitized, challenged; vehicle, sensitized, challenged, drug vehicle only; olopatadine, 
sensitized, challenged, 0.1% topical olopatadine; alcaftadine, sensitized, challenged, 
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Figure 2 Eosinophil infiltration of conjunctiva. Confocal images of tissue sections 
from each treatment group stained for eosinophil-specific major basic protein (green) 
and counterstained with propidium iodide (red). A) No sensitization, no challenge 
(NS/NC;  naïve  animals);  B)  Sensitized,  challenged  (S/C);  C)  S/C  +  drug  vehicle; 
D) S/C + 0.1% topical olopatadine; E) S/C + 0.025% topical alcaftadine. Major basic 
protein staining is most pronounced in sensitized, challenged animals without drug 
treatment (B and C).
these experiments are shown in Figure 3. Sensitization 
and challenge induced a significant increase in eosinophils 
in the conjunctiva compared with the NS/NC group 
(P , 0.001). Treatment with alcaftadine 0.25% significantly 
inhibited eosinophil recruitment to the conjunctiva 
(P , 0.001) while treatment with olopatadine 0.1% did not. 
A direct statistical comparison between olopatadine 0.1% 
and alcaftadine 0.25% treatment groups found that alcaf-
tadine 0.25% was statistically superior to olopatadine 0.1% 
for prevention of eosinophil recruitment (P , 0.05). 
  Alcaftadine 0.25% was also statistically superior to vehicle-
treated eyes for prevention of eosinophil recruitment to the 
conjunctiva (P , 0.001).
Expression of e-cadherin and ZO-1 was also examined 
with immunofluorescent staining and confocal microscopy 
(Figure 4). These images were used to derive a quantitative 
comparison of expression levels in each tissue (Figures 5A 
and 5B). The ZO-1 expression level was significantly 
decreased in the S/C group compared with the NS/NC control 
(P # 0.05). Alcaftadine 0.25% was statistically better at 
preventing this loss of ZO-1 expression compared with the 
S/C group (P , 0.05) and was not statistically different from 
the NS/NC control. Treatment with olopatadine 01% did not 
prevent ZO-1 expression loss. There was no significant 
  difference in E-cadherin expression levels between the 
NS/NC and S/C groups, but a mean decrease was seen in the 
S/C group (Figure 5B). Alcaftadine 0.25% was statistically 
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Figure 3 Quantitation of eosinophil infiltration. Sections stained with Giemsa and 
hematoxylin and eosin to allow for direct counting of eosinophils; counts are from 
three consecutive conjunctival tissue sections. The S/C, vehicle, and olopatadine 
treatment  groups  are  all  significantly  different  from  NS/NC  (*P  ,  0.01).  The 
alcaftadine  group  is  not  significantly  different  from  NS/NC.  Olopatadine  is  not 
significantly  different  from  S/C  or  from  vehicle,  but  alcaftadine  is  significantly 
different from both of these treatments (‡P , 0.01). The alcaftadine group is also 
significantly different from the olopatadine group (†P , 0.05).
Abbreviations:  NS/NC,  no  sensitization,  no  challenge  (naïve  animals); 
S/C,  sensitized,  challenged;  vehicle,  sensitized,  challenged,  drug  vehicle  only; 
olopatadine, sensitized, challenged, 0.1% topical olopatadine; alcaftadine, sensitized, 
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Figure 4 Labeling of tight junctional proteins in conjunctiva. Immunofluorescent staining 
of ZO-1 (red) and E-cadherins (green) in tissue sections from five treatment groups. A) 
No sensitization, no challenge (naïve animals); B) Sensitized, challenged; C) Sensitized, 
challenged, drug vehicle only; D) Sensitized, challenged, 0.1% topical olopatadine; E) 
Sensitized, challenged, 0.025% topical alcaftadine. Note decreased staining in sensitized, 
challenged animals without drug treatment (B and C).
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Figure 5 Alcaftadine prevents conjunctival allergen challenge-associated changes 
in  ZO-1  and  E-cadherin  in  conjunctival  epithelium.  Confocal  images  were  used 
to  calculate  relative  expression  of  tight  junction  proteins  in  five  groups.  ZO-1 
expression was significantly decreased in sensitized, antigen-challenged (S/C) tissue 
compared with control tissue (5A, *P # 0.05). Both alcaftadine and olopatadine 
prevented this decrease, but only alcaftadine values were significantly different from 
the S/C groups (**P # 0.05). Differences in fluorescence intensity in E-cadherin 
staining (5B) between naïve and antigen-challenged groups were not significant, but 
treatment did result in trend of lower expression that was reversed in both active 
treatment groups. The only comparison that did reach the level of significance was 
the increase seen in alcaftadine-treated samples compared with the S/C + vehicle 
group (***P # 0.05). 
Abbreviations:  NS/NC,  no  sensitization,  no  challenge  (naïve  animals);  S/C, 
sensitized, challenged; vehicle, sensitized, challenged, drug vehicle only; olopatadine, 
sensitized, challenged, 0.1% topical olopatadine; alcaftadine, sensitized, challenged, 
0.025% topical alcaftadine; ZO-1, zonula occludin 1.
superior at preventing loss of E-cadherin expression com-
pared with the S/C group (P , 0.05). Treatment with olopa-
tadine 0.1% did not result in a statistically significant change 
from the S/C control. E-cadherin expression increased in 
both active treatment arms.
Discussion
In this study, a murine model of allergic conjunctivitis was 
used to examine the effects of alcaftadine and olopatadine on 
several aspects of chronic conjunctivitis. Rather than 
  examining a range of concentrations, we tested each of these 
agents at the concentrations used clinically. Overall, 
s  ensitization and challenge induced a robust allergic response, Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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evidenced by increased clinical signs and symptoms, 
increased eosinophilia, and decreased expression of ZO-1 
and E-cadherin tight junction markers. Although there was 
no statistical significance, mean symptom scores were 
reduced in both active treatment arms (olopatadine 0.1% and 
alcaftadine 0.25%).
Alcaftadine significantly inhibited eosinophil recruit-
ment compared with both the S/C and olopatadine 0.1% 
treatment groups. While the mechanism for this unique 
action of alcaftadine is unknown, it has been shown to 
antagonize H2 and H4 histamine receptors in addition to its 
H1 receptor antagonism.12 Multiple effects on eosinophils, 
including chemotaxis, have been ascribed to histamine 
binding effects at H4 receptors.16 Antagonism of these 
effects by alcaftadine could account for the reduced eosino-
phil infiltration. Previous studies have shown that olopata-
dine is a potent mast cell stabilizer,17 so it is unlikely that 
the eosinophil inhibition demonstrated by alcaftadine is due 
to a heightened suppression of mast cell degranulation. 
Furthermore, if the mast cell stabilization profiles of olo-
patadine and alcaftadine were significantly different, then 
it follows that differences would have also been apparent 
in acute clinical signs and symptoms. Because this was not 
the case, it is possible that the eosinophil inhibition dem-
onstrated by alcaftadine 0.25% is the result of an effect 
mediated via its broad spectrum of histamine receptor 
antagonism. Alternatively, higher doses of olopatadine may 
elicit similar effects on eosinophils as those observed with 
alcaftadine.
Alcaftadine 0.25% also demonstrated an ability to 
protect epithelial tight junction protein markers from 
allergic inflammation-based degradation. Conjunctival 
allergen challenge induced a loss in ZO-1 and E-cadherin 
expression in S/C and vehicle-treated control groups. Both 
ZO-1 and E-cadherin levels were statistically superior to 
S/C controls in the alcaftadine 0.25% treatment group. 
In contrast, ol  opatadine failed to prevent ZO-1 degradation, 
and was not significantly different from sensitized 
and   challenged controls with regards to E-cadherin 
expression.
It is possible that the prevention of tight junction protein 
loss demonstrated by alcaftadine 0.25% is related to the 
ability of the compound to prevent eosinophil recruitment. 
Following chemotaxis, eosinophils release granular contents 
in the conjunctival epithelium.3 The release of toxic cellular 
products, including eosinophil cationic protein and eosinophil 
peroxidases, is known to cause additional tissue damage, 
resulting in what is viewed clinically as the “late-phase” 
allergic response (also known as a “late-phase reaction”).3 
An in vitro study completed in an allergic asthma model 
found that presence of eosinophils in the respiratory epithe-
lium led to reductions in E-cadherin expression, potentially 
contributing to disease pathogenesis.18 These results were 
supported by an in vivo study in a guinea pig model of nasal 
allergy which concluded that eosinophil recruitment was 
responsible for E-cadherin loss and that epithelial cell contact 
mediated by E-cadherin is loosened as a consequence of 
eosinophil infiltration.19 To date, no published work has 
discussed the implications of eosinophilia on tight junction 
markers in ocular allergy. However, the mechanistic similari-
ties between these nasal and ocular allergic conditions sup-
port eosinophil inhibition as the mechanism by which 
alcaftadine protects the conjunctival epithelium. Further 
investigation into the mechanism of action of alcaftadine and 
its application for the   treatment of human allergic diseases 
is warranted.
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